Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2026)

Mirum Pharmaceuticals' Convertible Debt history runs 4 years deep, the most recent figure standing at $310.3 million for Q1 2026.

• In Q1 2026, Convertible Debt rose 0.56% year-over-year to $310.3 million; the TTM figure through Mar 2026 stood at $310.3 million (up 0.56% YoY), while the FY2025 annual figure was $309.8 million, up 0.56% from the prior year.
• Convertible Debt was $310.3 million for Q1 2026 at Mirum Pharmaceuticals, roughly flat from $309.8 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $310.3 million in Q1 2026 to a low of $305.6 million in Q2 2023.
• Historically, Convertible Debt has averaged $307.9 million across 4 years, with a median of $307.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Convertible Debt gained 0.53% in 2024, then grew 0.56% in 2026.
• A 4-year view of Convertible Debt shows it stood at $306.4 million in 2023, then gained by 0.54% to $308.1 million in 2024, then climbed by 0.56% to $309.8 million in 2025, then grew by 0.15% to $310.3 million in 2026.
• The last three Convertible Debt figures came in at $310.3 million (Q1 2026), $309.8 million (Q4 2025), and $309.4 million (Q3 2025), per Business Quant data.